DSP Nifty Healthcare Index Fund - Direct (G) - Mutual Fund Analysis | Complete Fund Review with Performance, Portfolio, and Risk Analysis
Comprehensive analysis of DSP Nifty Healthcare Index Fund - Direct (G) (45756) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
DSP Nifty Healthcare Index Fund - Direct (G)
DSP Investment Managers Private Ltd
The investment objective of the Scheme is to generate returns that are commensurate with the performance of the Nifty Healthcare Index, subject to tracking error. There is no assurance that the investment objective of the Scheme will be achieved.
Fund Health Radar
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Performance
Weak Returns
Risk
High Risk
Expenses
Low Expense Ratio
Portfolio Mix
Equity Focused
Management
New Team
Quality Score
Average Quality
DSP Nifty Healthcare Index Fund - Direct (G) - NAV History (1Y)
Showing 1Y NAV history
Performance across different time periods
Neutral Entry Point
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Neutral Entry Point
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Key Factors Analysis
1-Year Returns
Recent performance momentum
Alpha Generation
Outperformance vs benchmark
Equity Exposure
Market exposure level
Cost Efficiency
Fund management costs
Risk Assessment
Risk-adjusted returns
Long-term Track Record
Historical performance consistency
Management Stability
Fund manager experience
Fund Size
Assets under management
Investment Timing Insights
3Y Performance Comparison
This fund has underperformed its benchmark by 0.45% over the 3Y period.
See how your money can grow and compare with popular investment options
Your Investment
Compare With Popular Options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
Risk Metrics (3 Years)
Risk Level
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 18.51% |
| Max Healthcare Institute Ltd | Healthcare | 9.31% |
| Cipla Ltd | Pharmaceuticals | 8.79% |
| Divis Laboratories Ltd | Pharmaceuticals | 8.42% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 7.78% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 7.62% |
| Lupin Ltd | Pharmaceuticals | 4.69% |
| Fortis Healthcare Ltd | Healthcare | 4.49% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals | 3.93% |
| Laurus Labs Ltd | Pharmaceuticals | 3.44% |
Compare against Index Fund category average
Performance Summary
This comparison shows how the fund performs relative to the Index Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Index Fund category
DSP Nifty Healthcare Index Fund - Direct (G) vs Category Average
Similar Funds Comparison
| Fund Name | NAV | 1W | 1M |
|---|---|---|---|
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (IDCW) | ₹1247.44 | 0.28% | -0.89% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (G) | ₹1247.44 | 0.28% | -0.89% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (G) | ₹1242.74 | 0.27% | -0.90% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (IDCW) | ₹1242.72 | 0.27% | -0.90% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (G) | ₹1220.00 | 0.15% | 0.28% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (IDCW | ₹1220.00 | 0.15% | 0.28% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (IDCW) | ₹1215.39 | 0.15% | 0.27% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (G) | ₹1215.38 | 0.15% | 0.27% |
| HDFC BSE Sensex Index Fund - Direct | ₹792.87 | -0.28% | 0.07% |
| HDFC BSE Sensex Index Fund - Regular | ₹773.82 | -0.28% | 0.06% |
Category Average Returns
Anil Ghelani
A seasoned investment professional with over 1 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.